Influence of interleukin-6 on the invasiveness of human colorectal carcinoma

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4607-4614

  Hsu, Chi Pin ^a   Chung, Yuan Chiang ^b  

^a YUANPEI UNIVERSITY   (Taiwan)

^b TAO YUAN GENERAL HOSPITAL   (Taiwan)

Author keywords

Colorectal carcinoma; Interleukin 6; Invasion; SW480

Indexed keywords

INTERLEUKIN 6;

ARTICLE; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; CHEMOTAXIS; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; NEOPLASM INVASIVENESS;

EID: 33845919223     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Hirano T, Yasukawa K, Harada H et al: Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76, 1986.
2. Ishihara K and Hirano T: Interleukin-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13: 357-368, 2002.
3. Nian M, Lee P, Khaper N and Liu P: Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94: 1543-1553, 2004.
4. Kurzrock R: Cytokine deregulation in hematological malignancies: clinical and biological implications. Clino Cancer Res 3: 2581-2584, 1997.
5. Trikha M, Corringham R, Klein B and Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rational and clinical evidence. Clin Cancer Res 9: 4653-4665, 2003.
6. Burger RA, Grosen EA, Ioli GR et al: Spontaneous release of interleukin-6 by primary culture of lymphoid and tumor cell populations purified from human ovarian carcinoma. J Interferon Cytokine Res 15: 255-260, 1995.
7. Wu CW, Wang SR, Chao MF et al: Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91: 1417-1422, 1996.
8. Lu C, Sheehan C, Rak JW et al: Endogenous interleukin-6 can function as an in vivo growth stimulatory factor for advanced stage human melanoma cells. Clin Cancer Res 2: 1417-1425, 1996.
9. Oka M, Iizuka N, Yamamoto K et al: The influence of interleukin-6 on the growth of human esophageal cancer cell lines. J Interferon Cytokine Res 16: 1001-1006, 1996.
10. Kawano M, Hirano T, Matsuda T et al: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myeloma. Nature 332: 83-85, 1988.
11. Miki S, Iwano M, Miki Y et al: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinoma. FEBS letter 250: 607-610, 1989.
12. Riedel F, Zaiss I and Herzog D: Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 25: 2761-2766, 2005.
13. Salgado R, Junius S, Benoy I et al: Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103: 642-646, 2003.
14. George DJ, Halabi S, Shepard TF et al: The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostatic cancer: results from cancer and leukemic group B 9480 Clin Cancer Res 11: 1815-1820, 2005.
15. Chung YC and Chang YF: Serum interleukin-6 levels reflect the disease status of colorectal cancer J Surg Oncol 83: 222-226, 2003.
16. Kinoshita T, Ito H and Miki C: Serum interleukin-6 level reflects the tumor proliferate activity in patients with colorectal carcinoma. Cancer 85: 2526-2531, 1999.
17. Kishimoto T, Akira S, Narazaki M, et al: Interleukin-6 family of cytokines and gp 130. Blood 86: 1243-1254, 1995.
18. Taga T and Kishimoto T: GP130 and the interleukin-6 family of cytokines. Annu Rev Immuno 15: 797-819, 1997.
19. Heinrich PC, Behrmann I, Haan S et al: Principles of interleukin-6 type cytokine signaling and its regulation. Biochem J 374: 1-20, 2003.
20. Hirano T, Ishihara K and Hibi M: Roles of STAT3 in mediating the cell growth differentiation and survival signals related through the IL-6 family cytokine receptors. Oncogene 19: 2548-2556, 2000.
21. Jee SH, Chu CY, Chiu HC et al: Interleukin-6 induced basic fibroblast growth factor dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3 kinase/AKT pathway. J Invest Dermatol 123: 1169-1175, 2004.
22. Leu CM, Wong FH, Chang C et al: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathway. Oncogene 22: 7809-7818, 2003.
23. Köbel M, Budianto D, Schmitt WD et al: Influence of various cytokine on adhesion and migration of the colorectal adencarcinoma cell line HRT-18 Oncology 68: 33-39, 2005.
24. Lahm H, Petral-Malec D, Yilmaz-Ceyhan A et al: Growth stimulation of human colorectal carcinoma cell line by interleukin-1 and antagonistic effects of transforming growth factor β1. Euro J Cancer 28: 1894-1899, 1992.
25. Schneider MR, Hoeflich A, Fischer JR et al: Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151: 31-38, 2000.
26. Tsang KY, Kashmiri SV, Qi CF et al: Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression. Immunol Lett 36: 179-185, 1993.
27. Dansky-Ullmann C, Salgaller M, Adams S et al: Synergistic effects of IL-6 and TNF-r on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous TFN-β. Cytokine 7: 118-129, 1995.
28. Lahm H, Suardet L, Laurent PL et al: Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor α. Br J Cancer 65: 341-346, 1992.
29. O'Brien S, Kantarjian H, Freireich E et al: CI-973, a new platinum derivative with potential anti-leukemic activity. Cancer Res 52: 4130-4134, 1992.
30. Jeha S, Luo XN, Beran M et al: Antisense RNA inhibitor of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cell. Cnacer Res 56: 1445-1450, 1996.
31. Cos S, Fernandez R, Guezmes A et al: Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 58: 4383-4390, 1998.
32. Brozek W, Bises G, Girsch T et al: Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumor progression. Euro J Cancer 41: 2347-2354, 2005.
33. Fukada T, Hibi M, Yamanaka Y et al: Two signals are necessary for cell proliferation induced by a cytokine gp 130: involvement of STAT 3 is antiapoptosis. Immunity 5: 449-460, 1996.
34. Moran DM, Mayes N, Koniaris LG et al: Interleukin-6 inhibits cell proliferation in a rat model of hepatoccellular carcinoma. Liver International 25: 445-457, 2005.
35. Spiotto MT and Chung TD: STAS 3 mediates IL-6 induced growth inhibition in the human prostate cancer cell line LN cap. Prostate 42: 88-98, 2000.
36. Bellido T, O'Brien CA, Roberson PK and Manolagas SC: Transcriptional activation of the P21 (WAF 1, CIP 1, SPI 1) gene by interleukin-6 type cytokine. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 273: 21137-21144, 1998.
37. Shin SI, Freedman VH and Risser R: Tumorigenicity of virus-transformed cell in nude mice is correlated specifically with anchorage independent growth in vitro. Proct Natl Acad Sci USA 72: 4435-4439, 1975.
38. Gui GP, Puddefoot JR, Vinson GP et al: Altered cell-matrix contact: a prerequisite for breast cancer metastasis? Br J Cancer 75: 623-633, 1997.
39. Sommers CL, Byers SW, Thompson EW et al: Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Res Treat 31: 325-335, 1994.
40. Thompson EW, Torri J, Sabol M et al: Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin Exp Metastasis 12: 181-194, 1994.
41. Chen Y, Pawlikowska L and Yao JS: Interleukin-6 involvement in brain anteriovenous malformation. Anu Neurol 59: 72-80, 2006.
42. Yao JS, Zhai W, Young WL et al: Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. Biochem Biophys Res Commun 342: 1396-1404, 2006.
43. Yang S, Hu S, Hsieh YC et al: Mechanism of IL-6-mediated cardiac dysfunction following trauma hemorrhage. J Mol Cell Cardiol 40: 570-579, 2006.
44. Wung BS, Hsu MC, Wu CC and Hsieh CW: Resveratrol suppresse IL-6-induced ICAM-gene expression in endothelial cells: effects on the inhibition of STAT 3 phosphorylation. Life Science 78: 389-397, 2005.
45. Wei LH, Kuo ML, Chen CA et al: Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT 3 pathway. Oncogene 22: 1517-1527, 2003.
46. Su JL, Lai KP, Chen CA et al: A novel peptide specifically binding to interleukin-6 receptor (gp 80) inhibits angiogenesis and tumor growth. Cancer Res 65: 4827-4835, 2005.
47. Suzuki A, Kanada T, Mitsuyama K et al: CIS 3/SOCS 3/SSI 3 play a negative regulatory role in STAT 3 activation and intestinal inflammation. J Exp Med 193: 471-481, 2001.
48. Yoshimura A, Mori H, Ohishi M et al: Negative regulation of cytokine signaling influences inflammation. Current Opin Immunol 15: 704-708, 2003.
49. Sommer U, Schmid C, Sobota RM et al: Mechanisms of SOCS 3 phosphorylation upon interleukin-6 stimulation contribuations of Src-and receptor-tyrosine kinase. J Biol Chem 280: 31478-31488, 2005.